Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial - Top-Institutions - MDSpire

Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial

  • By

  • Java Walladbegi

  • Roger Henriksson

  • Björn Tavelin

  • Anncarin Svanberg

  • Gunnar Larfors

  • Martin Jädersten

  • Fredrik Schjesvold

  • Aram Mahdi

  • Karin Garming Legert

  • Douglas E. Peterson

  • Mats Jontell

  • November 3, 2021

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Karolinska University Hospital
    Karolinska University Hospital

    Stockholm, Sweden

    Key Differentiators

    • Oncology
    • Hematology
    • Supportive Care

  • #2

    Uppsala University Hospital
    Uppsala University Hospital

    Uppsala, Sweden

    Key Differentiators

    • Hematology
    • Oncology
    • Clinical Trials

  • #3

    Oslo University Hospital
    Oslo University Hospital

    Oslo, Norway

    Key Differentiators

    • Hematology
    • Oncology
    • Supportive Care

  • #4

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Hematology
    • Supportive Care

  • #5

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Hematology
    • Supportive Care

Original Source(s)

Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial

  • by Java Walladbegi, Roger Henriksson, Björn Tavelin, Anncarin Svanberg, Gunnar Larfors, Martin Jädersten, Fredrik Schjesvold, Aram Mahdi, Karin Garming Legert, Douglas E. Peterson, Mats Jontell

  • November 3, 2021

Related Content

Combination of Lisaftoclax, Ixazomib, and Dexamethasone for Maintenance Therapy Following CAR-T in Patients with Transplant-Ineligible Relapsed/Refractory Ultra-High-Risk Multiple Myeloma: A Review of Two Cases and Relevant Literature

This Week’s CGT News: Lilly’s $7B In Vivo CAR-T Bet

Lilly moves to acquire Kelonia, plus gene therapy for deafness approved

  • April 27, 2026

  • 6 min
Case Report: Extranodal marginal zone B-cell lymphoma in the lateral ventricle: literature review